On the contrary, a number of studies (originating mostly from western countries) suggest that DLBCL “patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis”, including report that BCL6-rearranged DHL cases are phenotypically GCB, and exhibit markedly better survival rates compared to their BCL2 DHL counterparts, who were found to be largely ABC in phenotype [25]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.